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Conservative surgery for breast cancer
The search for some form of treatment for breast cancer, which is more acceptable to women than the hateful mutilation of total mastectomy, continues. The interesting paper by Greening and hiscolleagues (page 261)is the latest contribution to this search -a search which is by no means new -and it supports the idea that partial mastectomy with axillary dissection but no other form of therapy may be justified in very early and very carefully selected cases. What has to be proved is that conservative surgery alone in such cases gives results in terms of survival and local recurrence equal to those ofa more radical approach; and Greening, with a mean follow up of 38months in 26patients, has not ofcourse had time to show this with any certainty. The results so far are, however, very interesting and add to the evidence from somewhat comparable studies that there is a place for a conservative approach.
The criteria which Greening and his colleagues have required for quadrantectomy with axillary dissection are that the primary tumour is less than 2 em in diameter, is situated in the outer hemisphere ofthe breast, and that the axillary nodes are free from invasion both clinically and on histological examination. It would be interesting to have further details ofthe technique. Forexample if the tumour is in the lower outer quadrant, is a separate incision used for the axillary dissection? How far is the axilla cleared? What is done if the histology of the axillary nodes shows invasion when none had been suspected clinically -an error which every surgeon often makes? How much skin, if any, is sacrificed with the 0141-0768/78/0071-0246/$01.00/0 specimen and what is the final cosmetic appearance of the breast?
The objections which are raised by the more radically minded surgeon to conservative surgery are primarily two. The first is the increased local recurrencerateatthesiteofoperation, a factor which does not seem to be in dispute. The second is the possibility ofmulticentric areas ofcarcinoma in the affected breast. Pathologists differ widely on the incidence of multicentricity, but surgeons who practise very conservative surgery do not seem to have found second primary tumours arising frequently in breast tissue which has been left in situ; though presumably it may be difficult to distinguish a local recurrence from a new primary tumour. Another point of controversy is the survival time after conservative as opposed to radical surgery. Some surgeons, of whom Crile (Crile et aJ. 1973) is perhaps the best known, contend that the axilla, ifit is clinically normal, does not require dissection unless clinical invasion later becomes apparent; and this deferment ofaxillary dissection carries no penalty in terms of survival time. Others, ofwhom Atkins and his colleagues (1972) have produced convincing evidence in a large controlled trial, find that if the axilla is clinically normal, wide local excision (tylectomy) gives results equal (in terms of local recurrence and survival) to radical mastectomy, but the radical operation is superior on both counts when the axilla is clinically invaded. Every case in this trial received postoperative radiotherapy, those patients subjected to tylectomy having radiotherapy to the breast tissue in addition to the node areas.
Other trials of very conservative surgery are proceeding. Veronesi (1977) in Milan has a randomized trial between, on the one hand, radical mastectomy and, on the other, excision of the quadrant ofthe breast which bears the tumour, with dissection of the axilla and radiotherapy to the residual tissue in the homolateral breast. The trial is confined to Tl NO cases with primary tumours less than 2 cm in diameter. The cases selected are thus closely akin to Greening's, except that Veronesi, presumably worried by the thought of multicentricity, gives radiotherapy. Veronesi stated in 1966 that he hoped to have 500cases in the trial by the end of 1977.
The cardinal difficulty in reaching a decision about the treatment of breast cancer, and the variations in treatment justified at differing clinical stages, is the length oftime which it takes to evaluate results. A ten-year follow up on a sufficiently large numberofpatients is needed, and this requires either a very large institution or a single surgeon's lifetime, if enough very early cases are to be gathered for a controlled clinical trial of quadrantectomy with axillary dissection versus mastectomy and axillary dissection. That Greening and his colleagues are right in thinking that such a trial is both justifiable and ethical cannot be denied; it is the formidable difficultyand lapse of time before definite results can be seen which is daunting. Ifthe results ofthe limited operation proposed continue to be as good as they have hitherto been in the Royal Marsden series, the case would surely be proven in a shorter time. It is to be hoped that a further report on this series will emerge.
Two final points: First, it is, as Greening says, generally accepted 'that breast cancer is in most, if not all, cases a systemic disease at the time of diagnosis'. But this need not, in the early case, preclude the possibility of cure. The body has an immune surveillance mechanism which can deal with a light load and gives grounds for guarded optimism in the veryearly low grade case. Secondly, itdoes not seemproper that the surgeon who seesfew cases of breast cancer, and has no special interest in the disease or intention of a meticulous follow up, should embark on new procedures which remain unproven and on which he will be in no position to shed further light. The matter has, however, gone a lot further than this. In April 1977an agreement of intent on more stringent qualitative regulations was announced by the DHSS and the ABPI, which it was intended would be incorporated in the revised code of practice of the ABPI. The original code of practice which was issued in 1958 was formulated after consultation with the BMA. The new code will also take into consideration the views of the Department of Health and Social Security. Under the agreement of intent two classes of pharmaceutical advertising were recognized as previously: the full advertisement for new products, and the reminder advertisement for existing products (now renamed the abbreviated advertisement). Under the agreement it was laid down that the abbreviated advertisement would become limited in size, It would not be whole page in certain journals and had to be less than half page in others. Subsequently it transpired that it was the intention of the DHSS that any advertisement less than a whole page would not be more than half a page. Negotiations are still at a delicate stage on this point. Both the pharmaceutical industry and the medical publishers who were not consulted at the time of the agreement of intent are anxious for different reasons to preserve whole page advertising or single advertisements that occupy most of a page. The industry has reservations about the relative value of half-page advertising. These reservations could lead to a concentration of promotional expenditure on the full-page advertising of new products. If this does come about, it could result in new and more expensive drugs being prescribed at the expense of cheaper traditional remedies. In this case not only would the level of NHS drug expenditure rise, but the volume of advertising could fall still further, to the detriment of medical journals generally. The DHSS has listened to representatives from the medical publishers who are now more concerned at the potential situation than are the pharmaceutical industry. The whole question will have to be resolved before the revised code of practice can come into operation. Should the quality and quantity of professional advertising be an area of government activity and are the present proposals likely to achieve the original objectives of the Chancellor? Certainly there is no reason to believe that a reduction in advertising revenue will assist medical journals in their postgraduate role. It was against this background that the Medico-Pharmaceutical Forum meeting of I June 1977(seep 282)was held.
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